MarginsXMarginsX
Home › Markets › Health Care › ALLR

Allarity Therapeutics Inc. (ALLR)

ALLR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.8752
-8.24% on the day
Market cap
$13.9M
Nano cap
Revenue · 2025
$320K
Prior year not contiguous
Net income · 2025
-$11.2M
-3509.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/0001437749-26-010310-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerALLR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001860657
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$320K
Net income-$11.2M
Operating income-$12.6M
Net margin-3509.7%
Operating margin-3939.1%
Revenue growthNo prior-year revenue to compare
Cash$14.7M
Total assets$18.3M
P/E (computed)Net income was not positive
P/S (computed)43.5×

Warning signs

Cash runway
14.9 months
$17.0M cash at June 30, 2026
Share count, 1 year
+1.2%
2025-11-13 to 2026-11-12 · +210451.8% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the issuance date of these financial statements."
10-Q 2026-11-13
Cash and burn$17.0M cash; operating cash flow -$3.4M a quarter.Report 2026-06-30
Shares outstanding15,997,108 (2026-11-12); 15,811,886 a year earlier; 4,558,623 three years earlier. 3y figure adjusted for splits (1-for-600 overall).Cover page 2026-11-12
Reverse splits, 3 years2; latest 1-for-30 on 2024-09-11Source 2024-09-11
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the marketLatest 2026-01-29
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWolf & Company, P.C., Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$0-$3.4M-$2.6M$17.0M$22.3MNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
$25K-$2.8M-$4.5M$19.8M$21.5MNeeds four quarters10-Q 2026-05-15
Q4 2025
2025-12-31
Not filed-$3.4M-$3.2M$14.7M$1.4M$320K10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$2.8M-$3.4M$16.9M$1.4MNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
$0-$2.3M-$5.5M$17.8M$1.4MNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
$0-$2.7M-$2.7M$25.2M$1.4MNeeds four quarters10-Q 2026-05-15
Q4 2024
2024-12-31
Not filed-$7.5M-$3.2M$19.5M$2.7M$010-K 2026-03-30
Q3 2024
2024-09-30
Not filed-$11.6M-$5.4M$18.5M$1.3MNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B52026-10-30
Latest annual report
FORM 10-K
10-K2026-03-30
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-13
Latest current report
CURRENT REPORT
8-K2026-11-02
Latest proxy
PROXY STATEMENT
DEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 404 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.1%
1 month+9.7%
3 months-29.9%
Year to date-11.7%
1 year-19.8%
From 52-week high-46.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MRKRMarker Therapeutics Inc.$0.8286-4.76%$13.8M
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M
NEUPNeuphoria Therapeutics Inc.$2.48-2.75%$13.4M
CTXRCitius Pharmaceuticals Inc.$0.5276-1.40%$14.5M
TVRDTvardi Therapeutics Inc.$1.10-6.78%$14.7M
ACTUActuate Therapeutics Inc.$0.2680-7.59%$14.7M
CMMBChemomab Therapeutics Ltd. American Depositary Share$1.62+5.88%$13.0M
KYNBKyntra Bio Inc.$3.20-8.31%$13.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier